XPH(SZ:300147)2022-12-08 01:13Group 1: Company Development Plans - The company is focusing on the development of traditional Chinese medicine formula granules and is conducting research on processes and quality standards [3] - The company is optimistic about the market prospects for traditional Chinese medicine slices and aims to promote their industrialization [3] Group 2: Clinical Research and Collaborations - The first phase of clinical research on specific T cell adoptive immunotherapy for solid tumors in collaboration with Hospital 458 has been completed, and data is currently being organized [3] - The company is cautiously considering mergers and acquisitions as a path for external development, focusing on companies that complement its products, technology, and channels [4] Group 3: Strategic Partnerships - The company has signed letters of intent for cooperation with Hubei Tianji Traditional Chinese Medicine Slices Co., Ltd. and Anhui Dechang Pharmaceutical Slices Co., Ltd., and is progressing according to plan [4] Group 4: Sales and Growth - Jiujibiotech has made adjustments to its sales policies and is expected to achieve steady growth this year compared to last year [4] Group 5: Employee Stock Ownership Plan - The first phase of the employee stock ownership plan is being implemented according to the asset management contract [4]